Search

536 Result(s)
Sort by

STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
World water day 2019

World water day 2019

Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Pyramid® / Presponse®

Pyramid® / Presponse®

The pyramid®/presponse® family of vaccines provides broad coverage for BVD types 1 and 2, IBR, BRSV, PI3 and Mannheimia haemolytica with only a single dose.
global-top-employer

global-top-employer

For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Rabisin® / Raboral V-RG®

Rabisin® / Raboral V-RG®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
founding-member-of-QUTAC

founding-member-of-QUTAC

Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Respimat re-usable wins Pharmapack Eco-Design Award

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.